

# SHUKRA PHARMACEUTICALS LIMITED

R.O.: 3<sup>rd</sup> Floor, "VEER" House, Opp. WIAA, Judges Bungalows Road, Bodakdev,  
Ahmedabad-380054

Ph. (079) 27498515, Email.: [Info@relishpharma.com](mailto:Info@relishpharma.com), Website : [www.relishpharma.com](http://www.relishpharma.com)

CIN : L24231GJ1993PLC019079

## Audited Financial Results by Company

PART I		(Rs. in Lakhs)				
Statement of Standalone Audited Results for the Quarter and Year Ended 31/03/2017						
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended	
	(31/03/2017)	(31/12/2016)	(31/03/2016)	(31/03/2017)	(31/03/2016)	
(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
<b>I Revenue from Operation</b>	199.35	132.94	223.76	517.22	482.40	
<b>II Other income</b>	0.00	0.96	2.68	2.35	6.76	
<b>III Total Revenue (I + II)</b>	199.35	133.90	226.44	519.57	489.16	
<b>IV Expenses</b>						
(a) Cost of materials consumed	15.92	26.84	13.87	86.07	77.30	
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	8.86	(0.45)	68.58	12.03	91.23	
(d) Employee benefits expense Finance Cost	33.61	35.09	27.29	118.21	115.75	
(e) Finance Cost	0.41	0.00	0.07	0.58	0.13	
(f) Depreciation and amortisation expense	11.20	9.25	11.20	46.59	44.80	
(g) Other expenses	73.34	48.22	37.41	151.51	79.36	
<b>Total expenses</b>	143.34	118.95	158.42	414.99	408.57	
<b>V Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)</b>	56.01	14.95	68.02	104.58	80.59	
<b>VI Exceptional items</b>	0.00	0.00	40.62	0.00	40.62	
<b>VII Profit / (Loss) before extraordinary items and tax (V - VI)</b>	56.01	14.95	27.40	104.58	39.97	
<b>VIII Extraordinary items</b>	0.00	0.00	0.00	0.00	0.00	
<b>IX Profit before tax (VII- VIII)</b>	56.01	14.95	27.40	104.58	39.97	
<b>X Tax expense - Provision for taxation</b>	20.71	0.00	23.11	32.21	23.11	
<b>XI Net Profit / (Loss) or the period from continuing operations (VII-VIII)</b>	35.30	14.95	4.29	72.37	16.86	
<b>XII Profit/(loss) from discontinuing operations</b>	35.30	14.95	4.29	72.37	16.86	
<b>XIII Tax expense of discontinuing operations</b>	35.30	14.95	4.29	72.37	16.86	
<b>XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>	35.30	14.95	4.29	72.37	16.86	



# SHUKRA PHARMACEUTICALS LIMITED

R.O.: 3<sup>rd</sup> Floor, "VEER" House, Opp. WIAA, Judges Bungalows Road, Bodakdev,  
Ahmedabad-380054

Ph. (079) 27498515, Email.: [Info@relishpharma.com](mailto:Info@relishpharma.com), Website : [www.relishpharma.com](http://www.relishpharma.com)

CIN : L24231GJ1993PLC019079

XV	Profit (Loss) for the period (XI + XIV)	35.30	14.95	4.29	72.37	16.86
XVI	Earnings per equity share:	156.57	156.57	156.57	156.57	156.57
	(1) Basic	0.23	0.10	0.03	0.46	0.11
	(2) Diluted	0.23	0.10	0.03	0.46	0.11

- Notes: 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 30th May, 2017.
2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard 17.
3. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
4. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.

By Order of the Board of Directors

Place : Ahmedabad

Date : 30/05/2017

For, Shukra Pharmaceuticals Limited



Sujay Mehta

Director

DIN : 02145467

# SHUKRA PHARMACEUTICALS LIMITED

R.O.: 3<sup>rd</sup> Floor, "VEER" House, Opp. WIAA, Judges Bunglows Road, Bodakdev,  
Ahmedabad-380054

Ph. (079) 27498515, Email.: [Info@relishpharma.com](mailto:Info@relishpharma.com), Website : [www.relishpharma.com](http://www.relishpharma.com)

CIN : L24231GJ1993PLC019079

Standalone Statement of Assets and Liabilities			
		As at	As at
		(Current year end)	(Previous year end)
Particulars		(31/03/2017)	(31/03/2016)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' funds</b>		
	(a) Share capital	156.57	156.57
	(b) Reserves and surplus	1317.43	1250.78
	(c) Money received against share warrants	0.00	0.00
	<b>Sub-total - Shareholders' funds</b>	<b>1474.00</b>	<b>1407.35</b>
<b>2</b>	<b>Share application money pending allotment</b>	0.00	0.00
<b>3</b>	<b>Minority interest *</b>	0.00	0.00
<b>4</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	0.00	0.00
	(b) Deferred tax liabilities (net)	260.49	244.14
	(c) Other long-term liabilities	0.00	0.00
	(d) Long-term provisions	0.00	0.00
	<b>Sub-total - Non-current liabilities</b>	<b>260.49</b>	<b>244.14</b>
<b>5</b>	<b>Current liabilities</b>		
	(a) Short-term borrowings	3.60	3.60
	(b) Trade payables	45.68	25.55
	(c) Other current liabilities	22.36	0.00
	(d) Short-term provisions	34.18	0.00
	<b>Sub-total - Current liabilities</b>	<b>105.82</b>	<b>29.15</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1840.31</b>	<b>1680.64</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets	1181.67	1135.60
	(b) Goodwill on consolidation *	0.00	0.00
	© Non-current investments	4.44	4.15
	(d) Deferred tax assets (net)	0.00	0.00
	(e) Long-term loans and advances	0.00	0.00
	(f) Other non-current assets	0.00	9.27
	<b>Sub-total - Non-current assets</b>	<b>1186.11</b>	<b>1149.02</b>
<b>2</b>	<b>Current assets</b>		
	(a) Current investments	0.00	0.00
	(b) Inventories	31.62	43.65
	(c) Trade receivables	241.05	86.14
	(d) Cash and cash equivalents	52.07	174.43
	(e) Short-term loans and advances	302.42	179.51
	(f) Other current assets	27.04	47.89
	<b>Sub-total - Current assets</b>	<b>654.20</b>	<b>531.62</b>
	<b>TOTAL - ASSETS</b>	<b>1840.31</b>	<b>1680.64</b>

\* Applicable in the case of consolidated statement of assets and liabilities For Shukra Pharmaceuticals Limited

\*\*\*\*\*

*Sujata J. N. N. N.*  
Director/Authorised Signatory